Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 09:40 ET | Source: Research and Markets

Imfinzi (durvalumab) Industry Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F

Dublin, May 12, 2025 (GLOBE NEWSWIRE) -- The "Imfinzi (durvalumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...
February 19, 2024 04:38 ET | Source: Research and Markets

Small Cell Lung Cancer Therapeutics Market Forecast to Reach $10.87 Billion by 2028 Amid Advances in Early Detection and Treatment

Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "Small Cell Lung Cancer Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Growth in Small Cell Lung...
January 30, 2024 07:19 ET | Source: Research and Markets

Analysis of AstraZeneca's IMFINZI (Durvalumab) for Treating Malignant Pleural Mesothelioma (MPM): Regulatory Landmarks, Market Expansion, Intellectual Property, Future Challenges - Forecast to 2032

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "IMFINZI Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This comprehensive report...
December 14, 2022 08:03 ET | Source: Research and Markets

Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Next-Generation Sequencing is Helping in Identifying New Molecular Targets

Dublin, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The "Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast,...
October 09, 2020 04:24 ET | Source: Research and Markets

Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030

Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...
March 03, 2016 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016

TUSTIN, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...